EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS
SUMMARY The efficacy and safety of oral sildenafil citrate for the treatment of erectile dysfunction (ED) were assessed in a 12‐week placebo‐controlled study. Men with ED of organic, psychogenic, or mixed aetiology were randomised to placebo (n=166) or 50 mg sildenafil (n=163), with adjustment to 10...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 1998-09, Vol.52 (6), p.375-379 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 379 |
|---|---|
| container_issue | 6 |
| container_start_page | 375 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 52 |
| creator | Padma‐Nathan, H Steers, WD Wicker, PA |
| description | SUMMARY The efficacy and safety of oral sildenafil citrate for the treatment of erectile dysfunction (ED) were assessed in a 12‐week placebo‐controlled study. Men with ED of organic, psychogenic, or mixed aetiology were randomised to placebo (n=166) or 50 mg sildenafil (n=163), with adjustment to 100 mg or 25 mg based on efficacy and tolerability. Efficacy assessments included a global efficacy question, event log data, and an optional partner questionnaire. At the end of the study, improved erections were reported by 74% of patients receiving sildenafil versus 16% for placebo (p |
| doi_str_mv | 10.1111/j.1742-1241.1998.tb08886.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17375460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17375460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4479-dfdfc9cfa72ef061ef53b554098ecebdd52344290940296fed50082e8d9832a83</originalsourceid><addsrcrecordid>eNqVkc1u1DAUhSMEEqXwDhZCrEjwb2J350kcGmSS0YxnMSsrkzjSjNJOiVvR7ngBJJ6RJ8FhRt3jja_sz-dc3xNF7xFMUFifDwnKKI4RpihBQvDkfgc552ny-CK6eL56GWqS8phBgl5Hb7w_QIgZ4_Ai-qXKssplvgWyLsBalspsQVOCZiU1WFe6ULUsKw2qGphrBcxKSfNN1WZm1ErlptIKFNt1ualD3dRXQIKi2Sy0-vPz90JXdfEJLLXM1aIJB3lTm1WjtQpWZlP8cyJYgKU0VRBdv41eDe3o3bvzfhltQkP5daybL6FLHXeUZiLuh37oRDe0GXYDTJEbGNkxRqHgrnO7vmeYUIoFFBRikQ6uZxBy7HgvOMEtJ5fRx5Pu3XT8_uD8vb3Z-86NY3vrjg_eooxkjKYwgFcnsJuO3k9usHfT_qadniyCdk7AHuw8ZjuP2c4J2HMC9jE8_nB2aX3XjsPU3nZ7_6yACQ8p0IDlJ-zHfnRP_2Fgq6_5clHOvxTkLyIfkm0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17375460</pqid></control><display><type>article</type><title>EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS</title><source>Wiley Journals</source><creator>Padma‐Nathan, H ; Steers, WD ; Wicker, PA</creator><creatorcontrib>Padma‐Nathan, H ; Steers, WD ; Wicker, PA ; Sildenafil Study Group</creatorcontrib><description>SUMMARY The efficacy and safety of oral sildenafil citrate for the treatment of erectile dysfunction (ED) were assessed in a 12‐week placebo‐controlled study. Men with ED of organic, psychogenic, or mixed aetiology were randomised to placebo (n=166) or 50 mg sildenafil (n=163), with adjustment to 100 mg or 25 mg based on efficacy and tolerability. Efficacy assessments included a global efficacy question, event log data, and an optional partner questionnaire. At the end of the study, improved erections were reported by 74% of patients receiving sildenafil versus 16% for placebo (p<0.0001). In the final 4 weeks of treatment, 65% of all attempts at sexual intercourse were successful for all patients (responders and non‐responders) receiving sildenafil versus 20% for placebo (p<0.001).The mean number of successful attempts per month was 5.9 for patients receiving sildenafil versus 1.5 for those receiving placebo (p<0.0001). The most common adverse events – headache, flushing, and dyspepsia – were generally mild to moderate in nature and rarely (<1%) a reason for discontinuation of treatment. Oral sildenafil is an effective, reliable and well‐tolerated treatment for ED of organic, psychogenic or mixed aetiology.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1742-1241.1998.tb08886.x</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Biological and medical sciences ; dyspepsia ; erectile dysfunction ; Genital system. Reproduction ; Medical sciences ; pharmaceuticals ; Pharmacology. Drug treatments ; sexual behavior ; sildenafil ; sildenafil citrate</subject><ispartof>International journal of clinical practice (Esher), 1998-09, Vol.52 (6), p.375-379</ispartof><rights>1998 John Wiley & Sons Ltd</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4479-dfdfc9cfa72ef061ef53b554098ecebdd52344290940296fed50082e8d9832a83</citedby><cites>FETCH-LOGICAL-c4479-dfdfc9cfa72ef061ef53b554098ecebdd52344290940296fed50082e8d9832a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1742-1241.1998.tb08886.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1742-1241.1998.tb08886.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2380254$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Padma‐Nathan, H</creatorcontrib><creatorcontrib>Steers, WD</creatorcontrib><creatorcontrib>Wicker, PA</creatorcontrib><creatorcontrib>Sildenafil Study Group</creatorcontrib><title>EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS</title><title>International journal of clinical practice (Esher)</title><description>SUMMARY The efficacy and safety of oral sildenafil citrate for the treatment of erectile dysfunction (ED) were assessed in a 12‐week placebo‐controlled study. Men with ED of organic, psychogenic, or mixed aetiology were randomised to placebo (n=166) or 50 mg sildenafil (n=163), with adjustment to 100 mg or 25 mg based on efficacy and tolerability. Efficacy assessments included a global efficacy question, event log data, and an optional partner questionnaire. At the end of the study, improved erections were reported by 74% of patients receiving sildenafil versus 16% for placebo (p<0.0001). In the final 4 weeks of treatment, 65% of all attempts at sexual intercourse were successful for all patients (responders and non‐responders) receiving sildenafil versus 20% for placebo (p<0.001).The mean number of successful attempts per month was 5.9 for patients receiving sildenafil versus 1.5 for those receiving placebo (p<0.0001). The most common adverse events – headache, flushing, and dyspepsia – were generally mild to moderate in nature and rarely (<1%) a reason for discontinuation of treatment. Oral sildenafil is an effective, reliable and well‐tolerated treatment for ED of organic, psychogenic or mixed aetiology.</description><subject>Biological and medical sciences</subject><subject>dyspepsia</subject><subject>erectile dysfunction</subject><subject>Genital system. Reproduction</subject><subject>Medical sciences</subject><subject>pharmaceuticals</subject><subject>Pharmacology. Drug treatments</subject><subject>sexual behavior</subject><subject>sildenafil</subject><subject>sildenafil citrate</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqVkc1u1DAUhSMEEqXwDhZCrEjwb2J350kcGmSS0YxnMSsrkzjSjNJOiVvR7ngBJJ6RJ8FhRt3jja_sz-dc3xNF7xFMUFifDwnKKI4RpihBQvDkfgc552ny-CK6eL56GWqS8phBgl5Hb7w_QIgZ4_Ai-qXKssplvgWyLsBalspsQVOCZiU1WFe6ULUsKw2qGphrBcxKSfNN1WZm1ErlptIKFNt1ualD3dRXQIKi2Sy0-vPz90JXdfEJLLXM1aIJB3lTm1WjtQpWZlP8cyJYgKU0VRBdv41eDe3o3bvzfhltQkP5daybL6FLHXeUZiLuh37oRDe0GXYDTJEbGNkxRqHgrnO7vmeYUIoFFBRikQ6uZxBy7HgvOMEtJ5fRx5Pu3XT8_uD8vb3Z-86NY3vrjg_eooxkjKYwgFcnsJuO3k9usHfT_qadniyCdk7AHuw8ZjuP2c4J2HMC9jE8_nB2aX3XjsPU3nZ7_6yACQ8p0IDlJ-zHfnRP_2Fgq6_5clHOvxTkLyIfkm0</recordid><startdate>199809</startdate><enddate>199809</enddate><creator>Padma‐Nathan, H</creator><creator>Steers, WD</creator><creator>Wicker, PA</creator><general>Blackwell</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>199809</creationdate><title>EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS</title><author>Padma‐Nathan, H ; Steers, WD ; Wicker, PA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4479-dfdfc9cfa72ef061ef53b554098ecebdd52344290940296fed50082e8d9832a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Biological and medical sciences</topic><topic>dyspepsia</topic><topic>erectile dysfunction</topic><topic>Genital system. Reproduction</topic><topic>Medical sciences</topic><topic>pharmaceuticals</topic><topic>Pharmacology. Drug treatments</topic><topic>sexual behavior</topic><topic>sildenafil</topic><topic>sildenafil citrate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Padma‐Nathan, H</creatorcontrib><creatorcontrib>Steers, WD</creatorcontrib><creatorcontrib>Wicker, PA</creatorcontrib><creatorcontrib>Sildenafil Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Padma‐Nathan, H</au><au>Steers, WD</au><au>Wicker, PA</au><aucorp>Sildenafil Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><date>1998-09</date><risdate>1998</risdate><volume>52</volume><issue>6</issue><spage>375</spage><epage>379</epage><pages>375-379</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>SUMMARY The efficacy and safety of oral sildenafil citrate for the treatment of erectile dysfunction (ED) were assessed in a 12‐week placebo‐controlled study. Men with ED of organic, psychogenic, or mixed aetiology were randomised to placebo (n=166) or 50 mg sildenafil (n=163), with adjustment to 100 mg or 25 mg based on efficacy and tolerability. Efficacy assessments included a global efficacy question, event log data, and an optional partner questionnaire. At the end of the study, improved erections were reported by 74% of patients receiving sildenafil versus 16% for placebo (p<0.0001). In the final 4 weeks of treatment, 65% of all attempts at sexual intercourse were successful for all patients (responders and non‐responders) receiving sildenafil versus 20% for placebo (p<0.001).The mean number of successful attempts per month was 5.9 for patients receiving sildenafil versus 1.5 for those receiving placebo (p<0.0001). The most common adverse events – headache, flushing, and dyspepsia – were generally mild to moderate in nature and rarely (<1%) a reason for discontinuation of treatment. Oral sildenafil is an effective, reliable and well‐tolerated treatment for ED of organic, psychogenic or mixed aetiology.</abstract><cop>Oxford</cop><pub>Blackwell</pub><doi>10.1111/j.1742-1241.1998.tb08886.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 1998-09, Vol.52 (6), p.375-379 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17375460 |
| source | Wiley Journals |
| subjects | Biological and medical sciences dyspepsia erectile dysfunction Genital system. Reproduction Medical sciences pharmaceuticals Pharmacology. Drug treatments sexual behavior sildenafil sildenafil citrate |
| title | EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF 329 PATIENTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A25%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EFFICACY%20AND%20SAFETY%20OF%20ORAL%20SILDENAFIL%20IN%20THE%20TREATMENT%20OF%20ERECTILE%20DYSFUNCTION:%20A%20DOUBLE%E2%80%90BLIND,%20PLACEBO%E2%80%90CONTROLLED%20STUDY%20OF%20329%20PATIENTS&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Padma%E2%80%90Nathan,%20H&rft.aucorp=Sildenafil%20Study%20Group&rft.date=1998-09&rft.volume=52&rft.issue=6&rft.spage=375&rft.epage=379&rft.pages=375-379&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1742-1241.1998.tb08886.x&rft_dat=%3Cproquest_cross%3E17375460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17375460&rft_id=info:pmid/&rfr_iscdi=true |